Search company, investor...
Ciitizen company logo


Founded Year



Acquired | Acquired

Total Raised




About Ciitizen

Ciitizen develops an online healthcare data platform. It helps patients collect, organize and share their medical records digitally. It enables patients to have control of their health data. It was founded in 2017 and is based in Palo Alto, California. In September 2021, Ciitizen was acquired by Invitae.

Headquarters Location

3000 El Camino Real 5 Palo Alto Square, Suite 225

Palo Alto, California, 94306,

United States

Compete with Ciitizen?

Ensure that your company and products are accurately represented on our platform.

Ciitizen's Products & Differentiators

    Ciitizen Patient Data Platform

    Ciitizen’s customers can access the platform to visualize our ever-growing patient data repository, structure custom solutions with a database of scalable fully longitudinal, source verified PHR profiles, and securely interact with patients for clinical trials. On Ciitizen’s platform, we help Pharma partners understand trends in treatment patterns and outcomes and facilitate cohort identification; Diagnostic partners pair genomic data with clinical data, HIEs share patient data faster while remaining compliant with regulations; and a host of other functionalities. While we achieve incredible results for B2B customers, patients see tangible results. They are matched to a trial quicker, learning more about their condition, and engaged to be a true Ciitizen - so that all parties on the table can advance medicine faster.

Expert Collections containing Ciitizen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ciitizen is included in 2 Expert Collections, including Digital Health 150.


Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry


Digital Health

10,341 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Ciitizen Patents

Ciitizen has filed 7 patents.

The 3 most popular patent topics include:

  • Natural language processing
  • Computational linguistics
  • Machine learning
patents chart

Application Date

Grant Date


Related Topics




Natural language processing, Computational linguistics, Machine learning, Artificial intelligence, Tasks of natural language processing


Application Date


Grant Date



Related Topics

Natural language processing, Computational linguistics, Machine learning, Artificial intelligence, Tasks of natural language processing



Latest Ciitizen News

Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases

Dec 1, 2022

11/10 12/01/2022 | 07:31am EST Message : *Required fields – Ciitizen real-world data platform expansion helps advance research and potentially improve outcomes for patients with pediatric epilepsy and/or developmental delay – SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae's Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months. By engaging with a broader community, Invitae, a leader in the rare pediatric neurodevelopmental field, aims to create value for significantly more patients with rare diseases. Identifying and recruiting patients with rare diseases into clinical studies is difficult, making it challenging to understand the etiology, disease course, differences among subpopulations and the impact of novel treatments. The Rare Patient Network is a new approach to solving these challenges by directly engaging with the broader community of patients with rare neurodevelopmental conditions. "The Rare Patient Network is a proactive way to empower patients," said Terry Jo Bitchell, PhD., executive director of COMBINEDBrain. "Even before a diagnosis or without a diagnosis, families who are grappling with epilepsy or a developmental delay will have a way to help each other and themselves simply by using their own medical record as a resource. When a treatment comes along, this resource will already be there just waiting to be part of the solution." The Rare Patient Network enables patients with rare diseases to engage with Invitae's Ciitizen platform to participate in more clinical studies to help advance research without repeated requests from multiple sources for the same information. "With the launch of the Rare Patient Network, we aim to break down silos by building the largest database of patient-consented genetic and clinical data of patients with rare neurodevelopmental disease," said Robert Nussbaum, M.D., chief medical officer at Invitae. "We have an ambitious goal of recruiting thousands of new patients with pediatric epilepsy and/or development delay to Invitae's Ciitizen data platform to create this database." The data generated by Invitae's Ciitizen platform is comprehensive, leveraging the HIPAA right of access to gather full medical records, longitudinally, from all of the patients' sites of care. Patients have complete access to the records for their own use, can decide whether to participate in research and are also able to remain involved and informed about the research throughout a study, highlighting the benefits of this unique patient-centered research model. "By expanding Invitae's rare neurodevelopmental cohort, Invitae is creating a valuable, new dataset," said Eiry W. Roberts, M.D., Chief Medical Officer of Neurocrine Biosciences. "The data collected can be helpful to conducting rapid natural history studies, understanding of the patient population and disease severity and potentially paving the way for new precision treatments." For more information, visit . About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company's website at . Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that the expansion of its Ciitizen real-world data platform helps advance research and potentially improves outcomes for patients with pediatric epilepsy and/or developmental delay. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements. Invitae PR contact:

Ciitizen Frequently Asked Questions (FAQ)

  • When was Ciitizen founded?

    Ciitizen was founded in 2017.

  • Where is Ciitizen's headquarters?

    Ciitizen's headquarters is located at 3000 El Camino Real, Palo Alto.

  • What is Ciitizen's latest funding round?

    Ciitizen's latest funding round is Acquired.

  • How much did Ciitizen raise?

    Ciitizen raised a total of $20M.

  • Who are the investors of Ciitizen?

    Investors of Ciitizen include Invitae, Andreessen Horowitz, Section 32, Verily Life Sciences and Schox Venture Capital.

  • Who are Ciitizen's competitors?

    Competitors of Ciitizen include Mamotest and 7 more.

  • What products does Ciitizen offer?

    Ciitizen's products include Ciitizen Patient Data Platform.

Compare Ciitizen to Competitors

Citizen Logo

Citizen offers a mobile application. It provides real-time alerts of crimes and other incidents to a nearby location. It empowers users with the technology and information that is needed to stay safe. It was founded in 2017 and is based in New York, New York.

Evidation Logo

Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.


SnapHealth operates as an insurance comparison platform. It allows individuals to compare and enroll in health insurance plans according to their needs. The company's algorithm considers the available health background, active medication lists, and income levels to display suitable plans. It mainly serves businesses and individuals retiring before age 65. It was founded in 2018 and is based in Lancaster, Pennsylvania.


Tendo develops a software platform for healthcare. It helps to develop connections between patients, clinicians, and caregivers by creating software that provides a user-friendly experience. It was founded in 2020 and is based in Sacramento, California.

LifeOmic Logo

LifeOmic is the developer of a secure cloud service for the long-term storage, retrieval, analysis, and clinical use of information central to patient care. Its PHC platform integrates and indexes disparate sources including genomic, clinical, imaging, and population data. All of this data is added to a searchable and flexible repository for each patient to deliver precision treatments and accelerate research. LifeOmic's LIFE mobile apps use the Precision Health Clous to empower individuals to be more involved in and take action on their personal health and wellness goals.

LeanTaaS Logo

LeanTaaS provides software solutions combining lean principles, predictive analytics, and machine learning for core operational processes in hospital and infusion center operations. It increases patient access, decreases wait times, improves staff satisfaction, reduces healthcare delivery costs, and improves operational performance. The company was founded in 2010 and is based in Santa Clara, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.